Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275812 | 0.80 | KMT2A (0.72) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL28931492 | 0.77 | NPC1 (0.67) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL26932853 | 0.77 | KDM4E (0.66) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL28931488 | 0.76 | NPC1 (0.66) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL10393959 | 0.74 | KMT2A (0.64) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL462367 | 0.74 | GAA (0.66) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL13191740 | 0.73 | EPHX1 (0.67) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL16256687 | 0.73 | EPHX1 (0.63) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL5448135 | 0.73 | LMNA (0.69) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL2751717 | 0.73 | EPHX1 (0.97) | KDM4EKMT2AMEN1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339668-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | claimed |
| WO-2002044126-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | PPIG, PIN1, PPIH | KDM4E 3068/4885KMT2A 4656/4885MEN1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.